TPMT
Thiopurine S-methyltransferase
Also known as: TPMT_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P51580
- Gene
- TPMT
- Ensembl
- ENSG00000137364
- Chromosome
- 6
- Canonical length
- 245 aa
- Protein class
- Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins
OverviewNCBI Gene
This gene encodes the enzyme that metabolizes thiopurine drugs via S-adenosyl-L-methionine as the S-methyl donor and S-adenosyl-L-homocysteine as a byproduct. Thiopurine drugs such as 6-mercaptopurine are used as chemotherapeutic agents. Genetic polymorphisms that affect this enzymatic activity are correlated with variations in sensitivity and toxicity to such drugs within individuals, causing thiopurine S-methyltransferase deficiency. Related pseudogenes have been identified on chromosomes 3, 18 and X. [provided by RefSeq, Aug 2014]
Canonical amino-acid sequenceUniProt
245 residues, UniProt reviewed canonical sequence.
>P51580|TPMT
1 MDGTRTSLDI EEYSDTEVQK NQVLTLEEWQ DKWVNGKTAF HQEQGHQLLK KHLDTFLKGK
61 SGLRVFFPLC GKAVEMKWFA DRGHSVVGVE ISELGIQEFF TEQNLSYSEE PITEIPGTKV
121 FKSSSGNISL YCCSIFDLPR TNIGKFDMIW DRGALVAINP GDRKCYADTM FSLLGKKFQY
181 LLCVLSYDPT KHPGPPFYVP HAEIERLFGK ICNIRCLEKV DAFEERHKSW GIDCLFEKLY
241 LLTEKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against TPMT can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.26
- Highest tissue expression
- 72 nTPM
Expression across tissuesHPA
Tissue
- thyroid gland: 72 nTPM
- kidney: 71 nTPM
- liver: 64 nTPM
- rectum: 33 nTPM
- duodenum: 32 nTPM
- colon: 32 nTPM
Single-cell type
- colonocytes: 202 nCPM
- enterocytes: 164 nCPM
- hepatocytes: 113 nCPM
- esophageal apical cells: 107 nCPM
- urothelial cells: 105 nCPM
- epididymal efferent duct absorptive cells: 98 nCPM
Immune cell
- intermediate monocyte: 47 nTPM
- non-classical monocyte: 41 nTPM
- myeloid DC: 32 nTPM
- classical monocyte: 22 nTPM
- total PBMC: 17 nTPM
- T-reg: 16 nTPM
Brain region
- cerebral cortex: 15 nTPM
- cerebellum: 12 nTPM
- thalamus: 11 nTPM
- pons: 11 nTPM
- hypothalamus: 10 nTPM
- midbrain: 10 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.15
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.29
- DepMap mean gene effect
- 0.03
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 7% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- methylation
- nucleobase-containing compound metabolic process
- xenobiotic catabolic process
- xenobiotic metabolic process
Molecular functions
- S-adenosyl-L-methionine binding
- thiopurine S-methyltransferase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- S-adenosyl-L-methionine-dependent methyltransferase superfamily
- TPMT family
- Thiopurine S-methyltransferase
- Thiopurine S-methyltransferase (TPMT)
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads TPMT as an antibody target. Whether an autoantibody or antibody against TPMT could matter depends on whether native TPMT is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
TPMT is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label TPMT as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...